You have accessJournal of UrologyPenis/Testis/Urethra: Benign & Malignant Disaese (I)1 Apr 2013706 EXTERNAL VALIDATION OF THE HEIDENREICH CRITERIA FOR THE SELECTION OF PATIENTS FOR UNILATERAL OR BILATERAL POST CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOR RESIDUAL MASSES OF TESTICULAR CANCER Cedric Vallier, Pierre-Henri Savoie, Jean Robert Delpero, Franck Bladou, Gwenaelle Gravis, Naji Salem, and Jochen Walz Cedric VallierCedric Vallier Marseille, France More articles by this author , Pierre-Henri SavoiePierre-Henri Savoie Marseille, France More articles by this author , Jean Robert DelperoJean Robert Delpero Marseille, France More articles by this author , Franck BladouFranck Bladou Montreal, Canada More articles by this author , Gwenaelle GravisGwenaelle Gravis Marseille, France More articles by this author , Naji SalemNaji Salem Marseille, France More articles by this author , and Jochen WalzJochen Walz Marseille, France, Metropolitan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.264AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The retroperitoneal lymph node dissection (RPLND) for residual masses after chemotherapy for metastatic non seminomatous germ cell tumor (NSGCT) is an invasive procedure. In selected cases, its invasiveness can be reduced by limiting the dissection to a unilateral, modified dissection field instead of a systematic full bilateral dissection. However, the selection of appropriate candidates for a modified RPLND is difficult. Heidenreich et al. proposed 2008 a modified RPLND in cases where the residual mass was in the primary landing zone of testis cancer and the residual mass measured <=5cm in diameter. The aim of our study was to validate these selection criteria. METHODS For validation, 59 patients that underwent retroperitoneal lymph node dissection for residual masses of NSGCT were used. Of these patients, 23 (39%) qualified for a modified RPLND, the others had an indication for a bilateral dissection. Results from histopathology after RPLND and follow-up data for relapse inside or outside the zone of the resection template were considered for validation. RESULTS In the study cohort, median age at time of RPLND was 31 years. The histopathological results showed necrosis in 24 (41%), teratoma in 29 (47%) and vital cancer in 7 (11%) patients. Overall, 8 (14%) relapses were observed after a median follow-up of 54 month. Of these, 6 were outside of the resection field and 2 were in-field. Of the 23 patients with indication for a modified RPLND, 1 patient relapsed in the contralateral testis and 1 inside the modified RPLND template. No relapse was observed outside the modified RPLND field and inside the untouched contralateral PRLND field. The Heidenreich criteria did therefore not misclassify a single patient. The 2 year disease free survival was 90% and 96% for the bilateral and the modified RPLND patients, respectively. Main limitation of the study is the low number of patients and its retrospective nature, a limitation shared with many testicular cancer series. CONCLUSIONS The Heidenreich criteria for the selection of candidates for a modified RPLND for residual masses after chemotherapy for NSGCT allows a highly reliable selection of patients. No patient with a modified RPLND relapsed in the contralateral RPLND field that was left untouched. The application of the Heidenreich criteria can help to significantly reduce comorbidity and invasiveness of RPLND. Ideally validation in larger multicenter series should be performed. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e290 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Cedric Vallier Marseille, France More articles by this author Pierre-Henri Savoie Marseille, France More articles by this author Jean Robert Delpero Marseille, France More articles by this author Franck Bladou Montreal, Canada More articles by this author Gwenaelle Gravis Marseille, France More articles by this author Naji Salem Marseille, France More articles by this author Jochen Walz Marseille, France, Metropolitan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Read full abstract